Ariceum Therapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
3
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Not Applicable
1 (33.3%)Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Phase 1
Recruiting
- Conditions
- Small Cell Lung Cancer Extensive StageMerkel Cell Carcinoma
- Interventions
- Drug: 225Ac-SSO110 + SoC
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Ariceum Therapeutics GmbH
- Target Recruit Count
- 50
- Registration Number
- NCT06939036
- Locations
- 🇺🇸
Biogenix Molecular, Miami, Florida, United States
🇺🇸University of Louisville Health-Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸United Theranostics, Glen Burnie, Maryland, United States
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Not Applicable
Completed
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Ariceum Therapeutics GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT05017662
- Locations
- 🇦🇺
Peter Maccallum Cancer Center, Melbourne, Australia
🇦🇺Ramsay Hollywood Private Hospital, Perth, Australia
🇦🇹Medical University of Vienna, Vienna, Austria
News
No news found